Sequent Scientific’s business development vice president resigns

Sequent Scientific Limited announced the immediate resignation of Ashish Kakabalia, vice president, business development and formulation, who was designated as senior management personnel. The resignation was communicated via a letter dated December 23, 2025, and is effective immediately.

The company stated that the disclosure is made in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025, and specifically references clause 7C of Part A of Schedule III of the SEBI Listing Regulations, alongside SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. The official announcement includes required disclosures in Annexure-A and Mr. Kakabalia's resignation letter in Annexure-B.

Mr. Kakabalia's resignation letter, addressed to the chief executive, Rajaram Narayanan of Alivira Animal Health Ltd, states that his departure is "as per our mutual discussion and understanding." He extended his best wishes to the company and its employees for the future. The company’s compliance officer, Yoshita Vora, formally informed both BSE Limited and the National Stock Exchange of India Limited about this development.